




PHARMACEUTICAL 2018

Aravive Inc.
Rank 161 of 342





PHARMACEUTICAL 2018

Aravive Inc.
Rank 161 of 342



The relative strengths and weaknesses of Aravive Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aravive Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 77% points. The greatest weakness of Aravive Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 114% points.

The company's Economic Capital Ratio, given in the ranking table, is 110%, being 64% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	81,708
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,593
Liabilities, Non-Current	0
Other Assets	11,271
Other Compr. Net Income	350
Other Expenses	-247
Other Liabilities	5,428
Other Net Income	-744
Other Revenues	40,000
Property and Equipment	798
Research and Development	94,612
Selling, General and Administrative Expense	29,870

Output Variable	Value in 1000 USD
Assets	93,777
Liabilities	11,021
Expenses	124,235
Revenues	40,000
Stockholders Equity	82,756
Net Income	-84,979
Comprehensive Net Income	-84,804
Economic Capital Ratio	110%